XML 132 R53.htm IDEA: XBRL DOCUMENT v3.10.0.1
SHARE CAPITAL (Narrative) (Details)
1 Months Ended 12 Months Ended
Jun. 13, 2018
USD ($)
shares
Apr. 12, 2017
USD ($)
shares
Feb. 15, 2019
USD ($)
shares
Dec. 31, 2018
USD ($)
shares
Dec. 31, 2017
USD ($)
shares
Apr. 30, 2018
CAD ($)
Dec. 31, 2016
shares
Statements Line Items              
Short form base shelf prospectus           $ 150,000,000  
Public equity offerings, net of issuance costs $ 35,700,000     $ 7,982,000      
Increase (decrease) in number of shares outstanding | shares 3,165,642            
Equity issuance, price per share $ 2.61            
Proceeds from issuing shares 8,273,000            
Commission $ 186,000            
Additional transaction costs       $ 105,000      
Maximum percentage of ownership of issued and outstanding shares       7.00%      
Share-based compensation expense       $ 1,976,000 $ 2,759,000    
Unvested share option expense not yet recognized       643,000 841,000    
Expense (recovery) on directors compensation related to deferred share units       $ (88,000) $ 484,000    
Deferred share units outstanding | shares       652,276 548,392   510,560
Deferred share units outstanding, fair market value       $ 1,407,000 $ 1,319,000    
Expense (recovery) related to share appreciation rights       $ (245,000) $ 139,000    
Share appreciation rights, outstanding | shares       694,000 911,993   579,660
Share appreciation rights outstanding, fair market value       $ 72,000 $ 341,000    
Preferred share units, authorized | shares       1,000,000      
Preferred share units granted | shares       446,000 200,000    
Preferred Share Units Vested | shares   325,000          
Performance share units, outstanding | shares       616,000 200,000   325,000
Share based compensation expense related to performance share units       $ 450,000 $ 101,000    
Increase in number of shares outstanding, settlement of preferred share units | shares   193,825          
Payments for settlement of performance share units   $ 449,000          
Description of instruments with potential future dilutive effect not included in calculation of diluted earnings per share       As of December 31, 2018, there are 4,978,300 anti-dilutive stock options (December 31, 2017 3,905,800 stock options).      
May 3, 2020 [Member]              
Statements Line Items              
Preferred Share Units Vested | shares       170,000      
May 3, 2021 [Member]              
Statements Line Items              
Preferred Share Units Vested | shares       446,000      
Events After Reporting Period [Member]              
Statements Line Items              
Increase (decrease) in number of shares outstanding | shares     635,171        
Equity issuance, price per share     $ 2.23        
Proceeds from issuing shares     1,419,000        
Commission     $ 32,000